Ra Capital Management buys $50,636,145 stake in Aclaris Therapeutics Inc (ACRS)

Aclaris Therapeutics Inc (ACRS) : Ra Capital Management scooped up 63,166 additional shares in Aclaris Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,627,719 shares of Aclaris Therapeutics Inc which is valued at $50,636,145.Aclaris Therapeutics Inc makes up approximately 5.88% of Ra Capital Management’s portfolio.

Other Hedge Funds, Including , Manufacturers Life Insurance Company The added ACRS to its portfolio by purchasing 4,110 company shares during the most recent quarter which is valued at $79,200.Tiaa Cref Investment Management boosted its stake in ACRS in the latest quarter, The investment management firm added 15,487 additional shares and now holds a total of 28,440 shares of Aclaris Therapeutics Inc which is valued at $548,039. Tfs Capital added ACRS to its portfolio by purchasing 33,223 company shares during the most recent quarter which is valued at $640,207. Aclaris Therapeutics Inc makes up approx 0.11% of Tfs Capital’s portfolio.Blackrock Investment Management boosted its stake in ACRS in the latest quarter, The investment management firm added 13,734 additional shares and now holds a total of 34,153 shares of Aclaris Therapeutics Inc which is valued at $658,128.California State Teachers Retirement System boosted its stake in ACRS in the latest quarter, The investment management firm added 6,683 additional shares and now holds a total of 18,896 shares of Aclaris Therapeutics Inc which is valued at $356,756.

Many Wall Street Analysts have commented on Aclaris Therapeutics Inc. Guggenheim Initiated Aclaris Therapeutics Inc on Jun 10, 2016 to “Buy”, Price Target of the shares are set at $35.

Aclaris Therapeutics Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate A-101 is being developed as an in-office treatment for seborrheic keratosis a non-cancerous skin tumor as well as for other cutaneous indications such as common warts. In addition the Company is engaged in developing a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions. The Company’s products A-201 and A-301 are indicated for the treatment of alopecia areata. The Company’s A-101 product is entering Phase III clinical trials for the treatment of seborrheic keratosis and Phase II clinical trials for the treatment of common warts. The Company’s A-201 and A-301 products are in pre- clinical stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *